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Interactions of LY333531 and Other
Bisindolyl Maleimide Inhibitors with PDK1
1999), as well as isoforms of PKC (Newton, 2001, 2003).
PKB, S6K, SGK, and certain isoforms of PKC are acti-
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Much attention has been devoted to a group of bisin-Georgetown University Medical Center
Washington, DC 20007 dolyl maleimide compounds that are based on the scaf-
fold of the nonspecific kinase inhibitor staurosporine
(reviewed in Goekjian and Jirousek, 1999). These BIM
compounds were originally reported to function as PKCSummary
selective inhibitors (Davis et al., 1992b), although subse-
quent work indicated that these were less specific thanLY333531, BIM-1, BIM-2, BIM-3, and BIM-8 are bisin-
dolyl maleimide-based, nanomolar protein kinase C originally thought (Davies et al., 2000). A structurally
related inhibitor termed LY333531 was also developed,inhibitors. LY333531, a PKC-specific inhibitor, is in
clinical trials against diabetes and cardiac ventricular which appeared to be more specific than other BIM
compounds and inhibited the PKC isoform with twohypertrophy complications. Specificity analysis with a
panel of 29 protein kinases reveals that these bisindo- orders of magnitude higher potency than other PKC
isoforms (Goekjian and Jirousek, 1999; Jirousek et al.,lyl maleimide inhibitors also inhibit PDK1, a key kinase
from the insulin signaling pathway, albeit in the lower 1996). Currently, LY333531 is in phase III clinical trials
as a therapeutic agent for prevention of diabetes compli-M range. To understand the molecular basis of inhibi-
tion, the PDK1 kinase domain was cocrystallized with cations such as diabetic retinopathy (Nakamura et al.,
1999), and also against left ventricular hypertrophy inthese bisindolyl maleimide inhibitors. The inhibitor com-
plexes represent the first structural description of this heart failure, the latter probably due to effects on cal-
cium sensitivity (Vlahos et al., 2003).class of compounds, revealing their unusual nonplanar
conformation within the ATP binding site and also ex- The BIM and LY333531 inhibitors chemically differ
from staurosporine by the lack of a second covalentplaining the higher inhibitory potential of LY33331 com-
pared to the BIM compounds toward PDK1. A combina- bond between the indole rings and by a change in
the head group from a lactam to a maleimide moietytion of site-directed mutagenesis and essential dynamics
analysis gives further insight into PDK1 and also PKC (Figures 1A–1F). These compounds are synthetically
more accessible than staurosporine, and a large numberinhibition by these compounds, and may aid inhibitor
design. of these derivatives have been synthesized (Figures 1B–
1E) (Davis et al., 1992a, 1992b). Absence of the second
bond linking the indole groups results in a nonplanarIntroduction
conformation, in contrast to the planar indolocarbazole
derivatives such as staurosporine (Figures 1A–1E) (Davis3-phosphoinositide dependent protein kinase-1 (PDK1)
et al., 1992b). LY333531 is similar to the BIM com-plays a key role in insulin and growth factor signaling
pounds, with an additional N12, N15-bridge linking thenetworks (Alessi, 2001). It phosphorylates and activates
two indole rings without forcing them into a flat confor-AGC (cAMP-dependent, cGMP-dependent, protein ki-
mation (Figure 1A) (Jirousek et al., 1996).nase C [PKC]) family kinases such as protein kinase B
In this study we describe and analyze the structures(PKB, also known as Akt) (Brazil and Hemmings, 2001),
of the protein kinase domain of PDK1 bound to thep70 ribosomal S6-kinase (S6K) (Avruch et al., 2001; Vo-
bisindolyl maleimide inhibitors BIM-1 (also known aslarevic and Thomas, 2001), serum and glucocorticoid
GF-109203X or Go¨ 6850; Toullec et al., 1991), BIM-2,responsive kinase (SGK) (Lang and Cohen, 2001), p90
BIM-3 (Fabre et al., 1993), BIM-8 (also known as Ro 31-ribosomal S6 kinase (RSK) (Frodin and Gammeltoft,
7549; Ohtsuka and Zhou, 2002; Zhou et al., 1999), and
LY333531 (Jirousek et al., 1996). These widely used in-*Correspondence: dava@davapc1.bioch.dundee.ac.uk
hibitors have not previously been crystallized with a5 Present address: Institute for Diabetes Research, Academic Hospi-
tal Schwabing, Ko¨lner Platz 1, 80804 Munich, Germany. protein kinase, and our results provide insight into their
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Figure 1. Two- and Three-Dimensional Representation of Bisindolyl Maleimides
(A–E) Two-dimensional representation of the kinase inhibitors used in this study, with numbering based on Takahashi et al. (1987). In addition,
the three-dimensional structures of the inhibitors as seen in complex with PDK1 kinase domain are shown. The refined ligand models from
the final refinement cycle are shown as stick representations with orange carbon atoms. Unbiased (i.e., before the ligand was included in the
refinement) |Fo|-|Fc|, φcalc maps are shown at 2.5 . Atoms from the flexible side chain of BIM-1 and BIM-2 that are not covered in electron
density (gray carbon atoms) were refined with occupancy set to zero.
(F) Two-dimensional drawing of UCN-01, also termed 7-hydroxy-staurosporine.
(G) Overall representation of the PDK1 kinase domain in complex with LY333531. A stick model of PDK1 is covered with a gray, semitransparent
surface. Residues of the ATP binding site are indicated by a green surface. The ligand is drawn as a stick representation with marine carbon
atoms. The N- and C lobes, as well as the linker or hinge region, are labeled, respectively.
mechanism of action. We support the structural data Results and Discussion
with specificity analysis, site-directed mutagenesis of
ATP binding site lining residues, and finally, essential Specificity of BIM and LY333531 Inhibitors
The specificities of LY333531, BIM-1, BIM-2, and BIM-8dynamics analysis of the kinase-inhibitor complexes,
the latter revealing a novel, inhibitor-induced conforma- were tested at a concentration of 10 M against a panel
of 29 protein kinases (Table 1). The specificity data fortional change.
PDK1-Bisindolyl Malemide Complexes
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Table 1. Specificity of LY333531, BIM-1, BIM-2, and BIM-8
Protein Kinase LY333531 (10 M) BIM-1 (10 M) BIM-2 (10 M) BIM-8 (10 M)
PKC 0  0 14  1 2  0 10  1
PDK1 11  3 43  6 61  4 14  3
MSK1 13  2 2  1 3  0 1  1
MAPKAP-K1a 15  15 1  1 3  3 21  2
S6K1 19  3 1  4 26  1 25  7
Chk1 22  1 13  3 17  1 5  2
GSK3 31  2 8  3 5  3 6  1
Phosphorylase kinase 35  2 6  1 7  0 2  1
AMPK 38  7 5  0 9  0 2  3
CDK2/cyclin A 39  2 42  8 25  14 34  3
PRAK 48  0 90  4 77  3 66  1
SGK 49  1 16  4 20  4 15  4
CSK 52  2 88  8 87  9 87  9
Lck 63  4 28  1 31  2 23  1
PKBph 67  3 41  1 46  2 30  1
MKK1 73  9 71  11 68  5 35  6
MAPKAP-K2 73  5 36  1 40  5 16  0
PKA 77  7 41  1 36  4 22  2
ROCK-II 79  3 89  12 82  15 33  0
SAPK2a/p38 87  1 99  3 86  10 38  11
DYRK1 93  4 3  1 4  1 2  0
JNK/SAPK1c 96  2 108  11 104  8 64  1
CK1 96  5 92  0 84  5 86  9
NEK6 96  6 61  5 75  8 21  4
MAPK2/ERK2 98  5 90  3 90  6 66  7
SAPK2b/p382 98  2 103  11 82  1 86  4
CK2 100  0 103  11 89  5 85  1
SAPK3/p38 100  3 101  11 93  7 75  4
SAPK4/p38 104  3 112  5 92  7 65  8
The indicated protein kinases were assayed at 0.1 mM ATP as described previously (Bain et al., 2003; Davies et al., 2000) in the absence or
presence of 10 M inhibitor. Results are presented as percentage of kinase activity compared to that in control incubations. The activity
results displayed in the two columns are an average of a triplicate determination. Abbreviations not defined in main text: MSK1, nuclear
mitogen- and stress-activated protein kinase-1; MAPKAP, MAP kinase-activated protein kinase; GSK3, glycogen synthase kinase 3; CDK2,
cyclin dependent protein kinase 2; SAPK, stress activated protein kinase; NEK6, NIMA (never in mitosis gene a)-related kinase 6; ROCK-II,
Rho-dependent protein kinase-II; AMPK, AMP-activated protein kinase; MKK1, MAP-kinase kinase-1; PRAK, p38-regulated/activated protein
kinase; CK2, Casein kinase-2; Chk1, cell cycle checkpoint kinase-1; DYRK, dual specificity tyrosine phosphorylated and regulated kinase;
CSK, C-terminal Src kinase.
BIM-3 were reported previously (Davies et al., 2000). Figure 1G, and initial |Fo|-|Fc|, φcalc electron density for
the ligands is shown in Figures 1A–1E.The results show that LY333531 is markedly more spe-
cific than the BIM inhibitors. At 10 M LY333531, a high
concentration of drug that completely abolishes PKC LY333531 Bound to the PDK1 Kinase Domain
activity, the activity of five other kinases was reduced The PDK1-LY333531 complex at 1.70 A˚ represents the
to 15%–30%, with the remainder of the enzymes in the highest resolution PDK1 structure available to date. The
panel being inhibited to a lesser extent (Table 1). In overall structure of the catalytic domain of PDK1 com-
contrast, in the presence of 10 M BIM inhibitors, 6–7 plexed to LY333531 is shown in Figure 1G. In initial
kinases were inhibited by 	90% and a further 4–10 in- electron density maps, strong (	3 ) |Fo|-|Fc|, φcalc den-
hibited by	70% (Table 1). Interestingly, we noticed that sity could be observed in the ATP binding site, cover-
LY333531 and all of the BIM compounds inhibited PDK1 ing all atoms of LY333531 (Figure 1A). Within PDK1,
by around 40% (BIM-2) to 90% (LY333531) at 10 M. LY333531 adopts a nonplanar conformation (Figure 1A)
The IC50 for PDK1 inhibition by LY333531 is 750 nM, for Theand indole rings of LY333531 have torsion angles
BIM-1 is 9 M, for BIM-2 is 14 M, for BIM-3 is 4 M, of 38
 for the C4b-C4c torsion and of 30
 for the C7a-
and for BIM-8 is 1 M. C7b torsion, respectively (Figures 1A and 2). This results
in a distance of 3.1 A˚ between the C13 and C14 carbon
atoms. The linker between N12 and N15 displays anOverall Structure of PDK1-Inhibitor Complexes
As the LY333531 and BIM inhibitors have not been crys- extended conformation, bridging a distance of 5.4 A˚.
LY333531 makes several contacts with the PDK1 kinasetallized with a kinase previously, we decided to cocrys-
tallize the inhibitor molecules with the previously crystal- domain (Figure 2). The indole rings form hydrophobic
interactions, with Leu88 (N lobe; see Figure 1G) andlized PDK1 catalytic domain (residues 51–359; Biondi et
al., 2002). Diffraction data collection, structure solution Gly165, Leu212 (C lobe) sandwiching the  indole ring,
and Val96, Lys111 (N lobe), and Thr222, Asp223 (C lobe)by molecular replacement, and refinement resulted in
the final models with statistics shown in Table 2. An packing against the indole ring. In the recently reported
structure of PDK1 in complex with staurosporine (Ko-overall picture of the PDK1 kinase domain is shown in
Structure
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Table 2. Data Collection and Refinement Statistics
PDK1-LY333531 PDK1-BIM-1 PDK1-BIM-2 PDK1-BIM-3 PDK1-BIM-8
Beamline ID14-EH2 ID14-EH1 ID14-EH1 ID14-EH1 ID14-EH2
Wavelength (A˚) 0.933 0.934 0.934 0.934 0.933
Space group P3221 P3221 P3221 P3221 P3221
Unit cell (A˚) a,b  121.62 a,b  122.40 a,b  121.95 a,b  121.63 a,b  123.68
c  47.875 c  48.02 c  48.07 c  48.02 c  47.79
Resolution (A˚) 25.0–1.70 (1.76–1.70) 25.0–2.50 (2.59–2.50) 25.0–1.90 (1.97–1.90) 25.0–1.95 (2.02–1.95) 25.0–2.80 (2.90–2.80)
Observed reflections 218856 (15901) 40461 (2832) 118992 (11353) 136516 (12803) 32999 (3180)
Unique reflections 44644 (4344) 13556 (1105) 32482 (3218) 29917 (2843) 9493 (915)
Redundancy 4.9 (3.7) 3.0 (2.6) 3.7 (3.5) 4.6 (4.4) 3.5 (3.5)
Completeness (%) 99.9 (98.6) 92.6 (75.6) 99.9 (99.8) 100 (100) 90.5 (90.3)
Rmerge 0.044 (0.278) 0.089 (0.549) 0.076 (0.592) 0.100 (0.586) 0.138 (0.518)
I/I 22.1 (4.7) 9.8 (2.0) 10.0 (2.7) 6.9 (2.7) 8.5 (2.0)
Reflections in test set 665 547 670 623 521
Rcryst 0.176 0.199 0.240 0.183 0.193
Rfree 0.204 0.259 0.279 0.224 0.245
Number of groups
Protein residues 276 278 281 277 285
Water 283 47 180 227 81
Ligand atoms 35 31 33 29 30
SO42 atoms 35 15 20 25 60
Glycerol atoms 54 42 24 48 20
Wilson B (A˚2) 19.6 53.3 22.2 20.7 50.2
B	 protein (A˚2) 18.9 41.3 23.5 23.5 28.9
B	 water (A˚2) 35.0 39.6 32.3 35.4 33.1
B	 ligand (A˚2) 14.5 50.5 25.0 19.6 29.5
Rmsd from ideal geometry
Bond length (A˚) 0.011 0.010 0.012 0.010 0.007
Bond angles (
) 1.45 1.72 1.43 1.73 1.66
Main chain B (A˚2) 0.86 1.49 0.73 1.44 1.38
Values between parentheses are for the highest resolution shell. All measured data were included in structure refinement.
mander et al., 2003), Val96 and Leu212 were identified as PDK1 in Complex with the Bisindolyl
Maleimides 1, 2, 3, and 8central hydrophobic residues contacting staurosporine
from the N-terminal and C-terminal lobes, respectively. Four structures of PDK1 in complex with BIM com-
pounds were determined. All structures showed |Fo|-In the PDK1-LY333531 complex, due to the nonplanar
nature of the ligand, these residues are 0.4 A˚ further |Fc|, φcalc electron density in the ATP binding site, at a
similar position as seen for LY333531 (Figures 1B–1E,apart than in the PDK1-staurosporine complex. The N12,
N15 bridge of LY333531 spans the ATP binding site of and 2). The maleimide head group and the  indole ring
of the four BIM compounds and LY333531 superimposePDK1 from the N lobe to the C lobe (Figure 2). C16
contacts the backbone of Leu88 and the C carbon of with an rmsd 0.3 A˚. Therefore, the head groups show
essentially the same hydrogen bonding pattern towardGly89 in the phosphate positioning loop of the N lobe.
Toward the C lobe, atoms C20 (Glu166, Glu209) and C21 the protein backbone (Figure 2; Table 3). Remarkably,
the  indole rings occupy the same space as the equiva-(Glu209, Asn210) contact the linker region between the
lobes (Figure 2). Electron density was also visible for lent group in LY333531 (maximal shift 0.6 A˚), contacting
Leu159, Val96, Lys111, and Thr222. This implies thatthe side chain extending from C19 (Figure 1A); however,
this moiety is more disordered (B	  25.5 A˚2 com- despite a different degree of rotational freedom of the
indole rings of BIMs versus LY333531, the  indole ringpared to B	  13.0 A˚2 for the rest of the ligand) and
is not involved in protein contacts. LY333531 makes adopts the same C7a-C7b torsion to fit the PDK1 ATP
binding pocket. The  indole ring is seen at an equivalentthree hydrogen bonds to the protein, from the maleimide
portion of the molecule. The O5 carbonyl oxygen hydro- position in all four BIM complex structures (maximal
shift between equivalent atoms: 0.2 A˚), but is flipped bygen bonds to the backbone nitrogen of Ala162, the imido
group (N6) hydrogen bonds to the backbone carbonyl of 180
 around the C4b-C4c bond compared to LY333531
(Figures 1A–1E, and 2). This arrangement of the indoleSer160, and the second carbonyl function at the seven-
position (O7) hydrogen bonds to O1 of Thr222 (Figure rings is also found in the small molecule crystal structure
for BIM-4 (Davis et al., 1992b), indicating that this confor-2; Table 3). Interestingly, the first two hydrogen bonds
mimic the interactions of the adenine base of ATP with mation is energetically favorable. The different orienta-
tion of the  indole ring of the BIM compounds makesPDK1, similar to all other kinase structures. Most ATP
competitive inhibitors characterized to date also display these molecules more compact (the largest distance
between C2-C9 in LY333531 is 10.9 A˚, compared toequivalent hydrogen bonds to the kinase backbone (Hu-
nenberger et al., 1999; Johnson et al., 1996). In contrast, 8.6 A˚ between C9 and N15 in BIM-3) and less stauro-
sporine-like compared to LY333531, resulting in fewerthe hydrogen bond from O7 to Thr222 is not conserved
and this will be discussed in more detail below. protein-ligand interactions. The carbonyl oxygen of
PDK1-Bisindolyl Malemide Complexes
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Figure 2. Stereo Representation of Ligand
Interactions within the ATP Binding Pocket
of PDK1
Ligand carbon atoms are colored in marine,
and protein carbon atoms are in orange. Wa-
ter molecules are shown as purple spheres.
Hydrogen bonds are indicated by black dot-
ted lines. A gray ribbon indicates the protein
backbone.
Ala162 (in LY333531, distance 3.4 A˚ from C3) is now is flipped in the BIM compounds, it maintains similar
stacking interactions to those observed for LY333531,4.4 A˚ away from C14 of BIM-3 and therefore does not
interact with the ligand (Figure 2). The distance between between Leu88 and Leu212. The  indole nitrogen N15
in the BIM compounds points toward the solvent-acces-C of Gly165 and the ligand increases from 3.5 A˚ (to C3
of LY333531) to 4.8 A˚ (to N15 of BIM-3), creating a void sible side of the ATP binding pocket. In BIM-3, two
ordered water molecules (B factors  34.4 A˚2, 43.3 A˚2)between the  indole ring and the linker region connect-
ing the two kinase lobes. Although the  indole ring are found between the linker region and the ligand, cre-
Structure
220
Table 3. IC50 Values and Hydrogen Bonding Potential of Maleimides and UCN-01 in Complex with PDK1
LY333531 BIM-1 BIM-2 BIM-3 BIM-8 UCN-01
IC50 (M) 0.75 9 14 4 1 0.006
Ligand O5-Ala162 N
dDA (A˚) 3.1 3.1 3.1 3.0 3.1 2.8
HB2 0.7 0.5 0.5 0.7 0.5 0.8
Ligand N6-Ser160 O
dDA (A˚) 2.9 3.0 2.7 2.9 3.0 2.9
HB2 0.6 0.6 0.6 0.6 0.6 0.8
Ligand O7-Thr222 O1
dDA (A˚) 3.0 3.0 3.1 3.0 3.0 3.0
HB2 0.7 0.6 0.6 0.6 0.7 0.6
Ligand N19-Glu166 O2
dDA (A˚) 3.0 2.7
HB2 0.5 0.5
Hydrogen bonds between inhibitors and PDK1 were calculated with WHAT IF (Vriend, 1990) using the HB2 algorithm (Hooft et al., 1996). This
algorithm gives a score between 0 (no hydrogen bond) and 1 (optimal hydrogen bond) to reflect hydrogen bond geometry (HB2 row). Donor-
acceptor distances (dDA) are also listed.
ating a hydrogen bonding network and contacting N15 compared to BIM-1 and BIM-2, which lack a side chain
capable of hydrogen bonding (Figures 1B–1E; Table 3).of BIM-3 (3.3 A˚), the backbone carbonyl of Ala162 (2.9 A˚),
and also N of Lys169 (3.1 A˚) (Figure 2). In contrast, Additionally, the terminal amino group in BIM-3 and
BIM-8 is likely to provide electrostatic interactions withno water molecules could be observed at equivalent
positions for BIM-1 or BIM-2 in complex with PDK1 the protein, and such interactions have been noted to
be beneficial for ligand binding in PKA (Hunenberger(Figure 2). In BIM-8, the N15 nitrogen possesses a methyl
group. The variable side chains attached to N13 of the et al., 1999). This observation could be used in future
inhibitor design. However, LY333531 does not possess indole ring distinguish the BIM inhibitors from each
other (Figures 1B–1E). These side chains are structurally this extra hydrogen bond, yet it is the only inhibitor with
an IC50 below 1M. A possible explanation for this couldless ordered in complex with PDK1, as indicated by
higher B-factors compared to the rest of the molecule be the contribution of entropic effects on ligand binding.
The indole rings (Figures 1B–1E) in the BIM compounds(e.g., for BIM-3: B	core  18.0 A˚2 versus B	side chain 
29.9 A˚2), as well as weak density for some atoms (Figures would be expected to have considerable rotational free-
dom in solution, yet are tethered in the PDK1 complexes.1B–1E).
In LY333531, however, the indole rings are not free to
rotate due to the presence of the additional N12, N15Correlation of IC50 with Hydrogen Bonding
bridge (Figure 1A), and consequently, a lower entropicThe hydrogen bonding of LY333531 and the BIM inhibi-
penalty would have to be paid upon binding to PDK1.tors with the PDK1 kinase domain was assessed using
Measurement of such potential entropic effects by iso-the HB2 algorithm (Table 3) (Hooft et al., 1996). All inhibi-
thermal titration microcalorimetry was not successfultors display three hydrogen bonds from the polar groups
due to weak solubility of the ligands.of their maleimide moieties (O5-Ala162, N6-Ser160, and
O7-Thr222), which appear to have equal strength (Table
3). As discussed above, two of these interactions are Comparison of LY333531 and UCN-01
Binding to PDK1highly conserved and also visible in the binding mode
of the adenine base in ATP (Biondi et al., 2002), as well Compared to UCN-01 inhibition (IC50  0.006 M), the
inhibitors described here show a 100- to 2000-foldas with staurosporine and UCN-01 binding (Komander
et al., 2003). However, in the present structures both higher IC50 against PDK1. Apart from the weaker hydro-
gen bonds (Table 3), and the described putative entropicof these hydrogen bonds have poorer geometry for
both LY333531 and the BIM compounds compared to effects, it is possible that there are other features of the
staurosporine scaffold which contribute to its greaterUCN-01 (Table 3). The third maleimide hydrogen bond
from O7 to Thr222-O1 is also found in the complex of inhibitory potential. As the most staurosporine-like in-
hibitor, LY333531, is the most potent inhibitor with anPDK1 with UCN-01, which possesses a hydroxy group
instead of a second carbonyl group at the C7 position IC50 below 1 M, we compared the complexes of PDK1-
LY333531 and PDK1-UCN-01. As mentioned above,(Figure 1F). In the maleimide inhibitors, this hydrogen
bond displays similar geometry than observed for UCN-01 possesses a lactam head group and a 7-hydroxy
group, rather than a maleimide 7-carbonyl. The changeUCN-01 (Table 3). As mentioned above, different IC50
values are found for LY333531 and BIM inhibitors, with from a planar carbonyl C7 in LY333531 to a tetragonal C7
in UCN-01 places the hydroxy group out of the aromatic0.75 M (LY333531), 1 M (BIM-8), 4 M (BIM-3), 10 M
(BIM-1), and 14 M (BIM-2) (Table 3). BIM-3 and BIM-8 plane, toward the C lobe, where it makes a hydrogen
bond to Thr222 (Figures 1A and 1F; Table 3) (Komanderpossess an additional fourth hydrogen bond from the
terminal side chain amino group (N19) to the O2 of et al., 2003). However, superposition of both protein
structures (rmsd on main chain atoms: 0.42 A˚) showsGlu166 (Figure 2). It can be noted that the additional
hydrogen bond correlates with a 3- to 10-fold lower IC50 that the head groups of both ligands do not superim-
PDK1-Bisindolyl Malemide Complexes
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Figure 3. Conserved Carbon Positions in the
PDK1 ATP Binding Site
(A) Superposition of LY333531 (dark green)
and BIM-8 (magenta) bound to the PDK1-
UCN-01 complex (with PDK1 colored as in
Figure 2, and UCN-01 colored in marine). The
rotation of the maleimide head group as well
as conserved carbon positions within the
staurosporine scaffold are visible, with atoms
numbered as in Figure 1A.
(B) A carbon affinity grid (in yellow) shows the
preferred positions of carbon atoms within
the ATP binding site of the PDK1-UCN-01
complex. The grid is contoured at a binding
potential energy of 0.55 kcal/mol and is lo-
cated around conserved carbon positions for
UCN-01 (marine) and LY333531 (dark green).
(C) The same grid as in (B), with BIM-8 (ma-
genta) superimposed onto UCN-01 (marine).
pose, but display a tilt of approximately 20
 along the al., 2002). Chk1 binds the 7-hydroxy group of UCN-01
with Ser147-O (equivalent to Thr222) (Komander et al.,C4c-C5 axis of the maleimide compared to UCN-01 (Fig-
ure 3A). This results in a shift of the LY333531 O5 oxygen 2003; Zhao et al., 2002). However, no direct hydrogen
bond can be observed between Ser147-O and theof 0.5 A˚ toward the N lobe and in a shift of the N6
atom of 0.3 A˚ in the other direction. The largest distance 7-carbonyl oxygen of SB218078 (distance 4.4 A˚). Thus,
SB218078 does not orient itself to form a third hydrogenbetween equivalent atoms of the five-membered rings
is 0.6 A˚ for the C7 carbon. However, as a result of this bond, as observed for complexes of PDK1 with malei-
mides. This indicates that in Chk1, the hydrophobic in-different orientation, the 7-hydroxy group of UCN-01 and
the 7-carbonyl oxygen of LY333531 are positioned to teractions of the ligand with the kinase are more impor-
tant than the formation of an additional hydrogen bond,within 0.5 A˚. The rotation therefore enables the O7 of
LY333531 to hydrogen bond O1 of Thr222 (Figure 3A; and this finding is consistent with theoretical models
(Hunenberger et al., 1999).Table 3), but at the same time weakens the remaining
hydrogen bonds (Table 3). As mentioned above, the
maleimide head groups of the BIM compounds superim- Identification of Conserved Carbon Positions
in the PDK1 ATP Binding Sitepose with that of LY333531, and therefore these are
also tilted compared to UCN-01 (Figures 3A and 3C). It is surprising that although the maleimide head group
is rotated and the indole rings are tilted compared toHowever, such rotation of the maleimide head group is
not observed in the only other maleimide inhibitor pro- UCN-01, two aromatic C-C bonds of UCN-01 within the
indole rings closely overlap with the LY333531 indoletein kinase complex described to date. Structures of the
cell cycle checkpoint kinase Chk1 have been reported rings (Figure 3A). The bonds between C3 and C4 and
between C8 and C9 are shifted less than 0.15 A˚ inin complex with UCN-01 and the staurosporine analog
SB218078, which contains a maleimide head group the superimposed PDK1-UCN-01 and PDK1-LY333531
complexes, whereas other equivalent atoms shift up to(PDB codes 1NVQ, 1NVS) (Zhao et al., 2002). Both li-
gands inhibit Chk1, with apparent Ki’s of 5.6 nM 0.7 A˚ in the  indole ring and up to 1.9 A˚ in the  indole
ring (Figure 3A). This finding suggests that despite over-(UCN-01) and 15 nM (SB218078), respectively (Zhao et
Structure
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all differences in ligand orientation, the position of cer- PKC isoforms could be more beneficial for the geometry
of the remaining, conserved hydrogen bonds. BIM-3 andtain atoms is fixed within the ligand binding site. To
assess this on a more quantitative scale, the structure BIM-8 make an additional, fourth hydrogen bond toward
Glu166 in PDK1. In the PDK1[Glu166Asp] mutant, theof PDK1 in complex with UCN-01 was used to generate
an affinity grid for a carbon probe with AUTODOCK3 IC50 increases marginally (from 3.8 to 5.7 M), indicating
a potential positive contribution of this residue to ligand(Morris et al., 1998). This grid determines the energy of
interaction between isolated carbon atoms and the binding. As discussed above, in wild-type PDK1, Thr222
hydrogen bonds to O7 of LY333531 (Figure 2; Table 3).PDK1 ATP binding site. Consistent with the observed
superposition of particular carbon atoms at the C3-C4 However, the finding that both wild-type PDK1 and the
PDK1[Thr222Ala] mutant were similarly inhibited byand C9 positions, local minima were observed with bind-
ing energies of approximately 0.55 kcal/mol (Figures LY333531 indicates that this interaction does not con-
tribute significantly to LY333531 binding to PDK1, and3B and 3C). Interestingly, an additional local minimum
is observed around the ether carbon of the sugar moiety this was also observed for the binding of UCN-01 to
PDK1 (Komander et al., 2003). The remaining mutationsof UCN-01, which superimposes with C21 of the N12,
N15 bridge of LY333531, and also with C16 of the flexible would be anticipated to change the shape and volume
of the ATP binding pocket, but none were found toside chain of BIM compounds (Figures 3B and 3C). A
comparison with grids calculated for other probe atoms significantly influence the ability of PDK1 to be inhibited
by either LY333531 or BIM-3 (Table 4). We interpretshowed that carbon has the highest affinity to these
positions (data not shown). This suggests a preference these results as implying that the overall shape of the
ATP binding site, rather than one specific residue, isof PDK1 for carbon atoms at these particular positions,
which is satisfied by both staurosporine derivatives and responsible for the high-affinity binding of LY333531 to
PKCcompared to PDK1. This contrasts with other kinaseLY333531, but only partially (for the C9 and the C16
position) by the BIM compounds. Due to the flipped  inhibitors, such as the pyridinylimidazole SB203580 p38
MAP kinase inhibitor, where the presence of a smallindole ring, the BIM inhibitors do not occupy the favor-
able carbon positions equivalent to C3-C4 in LY333531, amino acid residue (Thr106 in p38) at a position occu-
pied by large amino acid residue in most other kinasesmaking these compounds less staurosporine-like (Fig-
ures 2 and 3). Interestingly, the most potent BIM inhibi- (e.g., Leu159 in PDK1), accounts for the specific inhibi-
tion of these enzymes by SB203580 (Eyers et al., 1998,tor, BIM-8, possesses a methyl group (C20) (Figures 1E,
3A and 3C) on N15, which occupies a position within 1999). However, we can of course not exclude that the
shape of the PKCATP pocket possesses other features1.1 A˚ of C3 in LY333531/UCN-01 (Figures 3A and 3C)
and therefore might account for increased affinity of the that account for the high-affinity binding to LY333531.
Another striking fact is the isoform specificity ofinhibitor. Whether the observed rotation of the malei-
mide head group occurs to satisfy a third hydrogen LY333531 toward PKC. PKC, which differs from PKC
by 6 nonconservative and 20 conservative mutationsbond, or to maximize hydrophobic interactions, can only
be speculated. The theoretical description of ligand within the kinase domain (all of which are remote from
the ATP binding site in a PKC model based on ourbinding determinants for PKA (Hunenberger et al., 1999)
seems to support the latter possibility. complex structure), is inhibited with an order of magni-
tude lower potency. All predicted residues contacting
the ligand would be identical between the - and 
LY333531 Inhibition of PKC-like PDK1 Mutants isoforms of PKC and are unlikely to account for the
As LY333531 is assumed to be a selective PKC inhibi- difference in inhibition. Therefore, other factors have to
tor, but no structural data for any PKC isoform is avail- contribute to the isoform specificity of LY333531, and
able to date, the basis for the selectivity and potency detailed (structural) analysis of PKC isoforms will be
of LY333531 for PKC is unknown. In an attempt to necessary to identify these factors. For instance, the
understand why, compared to PDK1, PKC is inhibited conformational state of the kinase domain could be a
two orders of magnitude more potently by LY333531, contributing factor to inhibitor potency, as will be dis-
the key residues in PDK1 which contact LY333531 and cussed in the following section.
differ in PKC (Val143, Leu159, Ala162, Glu166, and
Thr222) were mutated in PDK1 to their PKC equiva-
lents. The mutants generated were PDK1[Val143Thr], Essential Dynamics Calculation on Available
PDK1 StructuresPDK1[Leu159Met], PDK1[Ala162Val], PDK1[Glu166Asp],
PDK1[Thr222Ala], and the double mutant PDK1[Val143Thr, Analyses of protein kinase A (PKA) structures have high-
lighted the conformational flexibilities of protein kinasesThr222Ala]. These mutants possessed similar specific ac-
tivity toward the PDK1 peptide substrate as wild-type (Biondi et al., 2002; Johnson et al., 2001). The two lobes
of the kinase domain are connected via a hinge (FigurePDK1, and the IC50 for LY333531 and BIM-3 for the mu-
tants was determined (Table 4). The only mutation that 1G), which accounts for the mobility of the kinase lobes
relative to each other. For PKA, active, “closed” confor-marginally decreased the IC50 (from 750 nM to 500 nM
for LY333531 inhibition and from 3.8 to 2.5 M for BIM-3 mations and inactive, “open” conformations have been
described (Johnson et al., 2001). Certain inhibitors, suchinhibition) was PDK1[Val143Thr]. From analyzing the
PDK1-LY333531 structure, it appears that exchange of as staurosporine or balanol, bind to the PKA kinase
domain, locking it in an “intermediate” conformationVal143 to Thr could enable PDK1 to hydrogen bond the
O7 oxygen of the maleimide head group with better (Narayana et al., 1999; Prade et al., 1997). Therefore, it
may be necessary to study ligand-induced conforma-geometry. We therefore propose that this interaction in
PDK1-Bisindolyl Malemide Complexes
223
Table 4. IC50s of LY333531 Inhibition for PDK1 Mutants
PDK1 mutant Specific Activity (U/mg) IC50 LY333531 IC50 BIM-3
Wild type PDK1 158 750 nM 3.8 M
PDK1[Val143Thr] 153 500 nM 2.5 M
PDK1[Leu159Met] 147 600 nM 3.0 M
PDK1[Ala162Val] 156 743 nM 3.4 M
PDK1[Glu166Asp] 86 610 nM 5.7 M
PDK1[Thr222Ala] 157 734 nM 3.8 M
PDK1[Val143Thr/Thr222Ala] 180 500 nM 2.0 M
tional changes in protein kinases and design methods staurosporine and UCN-01 display the most closed con-
formations of PDK1. The bisindolyl maleimides describedthat include such information in the inhibitor design
process. in this study induce open conformations of PDK1. The
most open of the present PDK1 structures is the complexCompared to the recently reported structure of PDK1
in complex with staurosporine (Komander et al., 2003), with BIM-2, followed by BIM-3, BIM-1, and LY333531. The
second eigenvector describes a twisting motion betweentwo central hydrophobic residues (Val96 and Leu212)
are shifted by 0.4 A˚ upon binding of BIM inhibitors, which the N-terminal and the C-terminal lobe. Interestingly, all
PDK1-inhibitor complexes appear in a different “twistmay have an effect on the overall conformation of PDK1.
To investigate this, the overall conformational state of state” compared to the structures with PDK1’s natural
ligand ATP (Figure 4). This novel finding highlights thePDK1 was analyzed using an essential dynamics ap-
proach. This technique extracts large concerted mo- contribution of inhibitor binding to overall protein con-
formation.tions from an ensemble of structures (Amadei et al.,
1993) and has previously been applied to collections of
crystal structures (Biondi et al., 2002; de Groot et al., Conclusions
We have described the structures of the kinase domain1998; van Aalten et al., 1997, 2000). To assess the effect
of different ligands on the overall conformation of the of PDK1 in complex with the bisindolyl maleimide-based
inhibitors LY333531, BIM-1, BIM-2, BIM-3, and BIM-8.PDK1 kinase domain, we used structures of PDK1 in
complex with ATP (PDB id 1H1W) (Biondi et al., 2002), Apart from LY333531, which shows significant selectiv-
ity for PKC isoforms, bisindolyl maleimide inhibitors arestaurosporine (1OKY), UCN-01 (1OKZ) (Komander et
al., 2003), LY333531, BIM-1, BIM-2, BIM-3, BIM-8 (all not specific. Due to the lack of a second covalent linkage
of the indole rings compared to indolocarbazoles suchthis study), and unpublished structures of PDK1 with
MgAMPPNP, HisPDK1 (histidine-tagged PDK1) with as staurosporine, all ligands adopt a nonplanar confor-
mation in the ATP binding site of PDK1. This nonplanarMgADP, and PDK1 with a partially occupied ATP binding
site. All crystals were obtained under similar conditions conformation, however, is different between the BIMs
and LY333531 due to the N12, N15 bridge of the latter.and had the same space group and similar unit cell
dimensions. Using EDprep (A.W.S., unpublished data), We identified five effects that could contribute to ligand
affinity. First, the quality of conserved hydrogen bondsthe backbone atoms of the common core of the PDK1
structures were extracted. From the resulting models, seems to be correlated inhibitory potential. This was
deduced from the fact that a tilt in the maleimide headcomprising residues 74–230 and 244–357, a covariance
matrix was generated. Diagonalisation of this matrix group by 20
 enables a third hydrogen bond from the
ligand O7, but at the same time significantly affects theyielded a set of eigenvectors/eigenvalues describing the
concerted shifts of atoms. The projection of the PDK1 geometry of the remaining, conserved hydrogen bonds.
Second, addition of a side chain with a terminal aminostructures onto the subspace spanned by the first two
eigenvectors, which describe a hinge-bending motion group makes an additional hydrogen bond which mimics
the contact to the sugar moiety in both the ATP (Biondiand a twisting motion, respectively, is shown in Figure
4. A similar analysis of the concerted motions of avail- et al., 2002) and the staurosporine complexes (Ko-
mander et al., 2003) and has a positive effect on inhibi-able PKA structures (Biondi et al., 2002) showed that
the first two eigenvectors were found to describe quali- tion. Third, the chemical structure of the ligand contrib-
utes to affinity, as BIM compounds have a higher degreetatively similar motions (hinge bending and twisting), but
the magnitude of these motions seems to be signifi- of rotational freedom compared to LY333531 and stauro-
sporine, and therefore a higher entropic penalty is to becantly greater for PKA than for PDK1. This might reflect
a higher intrinsic flexibility of PKA, but it cannot be ex- paid upon fixing these molecules in the ATP binding site
of PDK1. Fourth, preferred positions for carbon atomscluded that experimental factors such as crystal packing
might contribute to the limited flexibility observed for within the ATP binding site of PDK1 were identified,
and the occupation of these sites is correlated with thePDK1.
The hinge bending, visualized by the first eigenvector, inhibitory potential. Finally, we provide evidence that
the overall protein conformation is also likely to play ahas also been described for other protein kinases, such
as PKA (Johnson et al., 2001) and CDK2 (Jeffrey et al., key role in inhibitor binding and specificity. Although the
bisindolyl maleimide inhibitors are neither specific nor1995), and results in their open (inactive) and closed
(active) conformations (Figure 4). The structures of PDK1 particularly good inhibitors of PDK1, their structures in
complex with PDK1 have lead to new insights into PDK1are distributed along the first eigenvector, indicating
different degrees of opening. PDK1 in complex with ligand binding with a novel class of inhibitors. Our find-
Structure
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Figure 4. Essential Dynamics Analysis of PDK1 Structures
(A) Projection of analyzed PDK1 crystal structures (labeled squares) onto the first eigenvector, describing the hinge-bending motion, and the
second eigenvector, describing the twisting motion, calculated from the PDK1 structures. The first two eigenvectors describe approximately
60% of the motions derived from PDK1 kinase structures. Abbreviations not explained in the text are STO (staurosporine) and Part (PDK1
with a partially occupied ATP binding site).
(B and C) Visualization of the motion described by the first (B) and second (C) eigenvector. The structures projected at 2 nm and 2 nm
total atomic displacements along the respective eigenvectors are shown, superimposed on the C lobe.
at 8.5 mg/ml. Crystals of PDK1-BIM-1 grew as orange rods fromings could be useful for the design of new PDK1 inhibi-
2.1 M ammonium sulfate, 0.1 M Tris-HCl (pH 7.5), and crystals oftors. Apparently a 7-hydroxy group (as in UCN-01) in-
PDK1-BIM-8 grew as brown stars of thin rods from 2.0 M ammoniumstead of a 7-carbonyl group (as in maleimides) may
sulfate, 0.1 M Tris-HCl (pH 7.75). Prior to data collection, crystals
improve the alignment of the remaining hydrogen bonds. were soaked in a cryoprotectant containing 1.7 M ammonium sul-
fate, 0.1 M Tris [pH 7.5], 20% (v/v) glycerol for 5 s and frozen in a
Experimental Procedures nitrogen cryo stream.
Protein Expression, Purification, and Crystallization
PDK1 (residues 51–359) was expressed in insect cells (SF21) and Data Collection and Structure Determination
Data on PDK1-inhibitor complexes were collected at the ESRFpurified as described previously (Biondi et al., 2002; Komander et
al., 2003). The protein was concentrated to 2 mg/ml (determined by beam-lines ID14-EH1 and ID14-EH2 (Table 1), using an ADSC Q4
CCD detector. The temperature of the crystals was maintained atBradford assay with BSA as a standard), mixed with 10% glycerol,
and frozen at80
C. Prior to crystallization, the glycerol was diluted 100 K using a nitrogen cryostream during the data collection. Data
were processed using the HKL package (Otwinowski and Minor,out with buffer A (500 mM NaCl, 25 mM Tris [pH 7.5]) during the
concentration process. 3 ml PDK1 at a concentration of 0.5 mg/ml 1997), with final statistics shown in Table 1. All datasets displayed
the space group P3221 with one molecule per asymmetric unit andwas mixed with 15 l LY333531 (10 mM in DMSO), incubated on
ice for 2 hr, and concentrated to 7.3 mg/ml. Dark purple, rod shaped were processed to 1.70 A˚ (LY333531), 2.50 A˚ (BIM-1), 1.90 A˚ (BIM-2),
1.95 A˚ (BIM-3), and 2.80 A˚ (BIM-8). The structure of PDK1 withcrystals were grown from 2.1 M ammonium sulfate, 0.1 M Tris-HCl
[pH 8.0], 10% (v/v) phenol using the vapor diffusion approach in a LY333531 was solved by molecular replacement with AMoRe (Na-
vaza, 2001) using the PDK1-ATP complex (PDB id 1H1W) (Biondisitting drop setup and reached a maximal size of 0.2  0.2  0.5
after 5 days. BIM-2 (45 l, 10 mM in 50% ethanol) and BIM-3 et al., 2002) as a search model, with an initial R factor of 28.1%
(Rfree, 30.1%). Refinement of the PDK1-BIM complexes was initiated(30 l, 10 mM in water) were preincubated with PDK1 (1.5 ml of
2 mg/ml solution each) and subsequently concentrated to 5.8 and by rigid body refinement in CNS (Brunger et al., 1998) using the
PDK1-ATP complex as a starting model. Initial R factors ranged6.1 mg/ml, respectively. Orange, rod-shaped crystals appeared in
2.3 M ammonium sulfate, 0.1 M Tris-HCl [pH 8.25] for PDK1-BIM-2 from 27.5% (Rfree  27.2%) for the PDK1-BIM-8 complex to 33.2%
(Rfree  35.4%) for the complex of PDK1 bound to BIM-3. Simulatedand in 2.2 M ammonium sulfate, 0.1 M Tris-HCl [pH 8.25] for PDK1-
BIM-3 in a sitting drop setup. BIM-1 and BIM-8 were cocrystallized annealing in CNS was used in the first rounds of refinement to
reduce model bias, and sequential rounds of model building in Owith PDK1 by adding 10 l BIM-1 (10 mM in ethanol) to 100 l PDK1
at 6.6 mg/ml or 5 l BIM-8 (50 mM in 30% ethanol) to 50 l of PDK1 (Jones et al., 1991) and refinement using CNS were performed. Final
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rounds of refinement for PDK1-LY333531 and PDK1-BIM-2 were and Alessi, D.R. (2000). Identification of a pocket in the PDK1 kinase
domain that interacts with PIF and the C-terminal residues of PKA.performed in REFMAC5 (Murshudov et al., 1997). Strong (	3.0 )
electron density in the ATP binding pocket was observed for all EMBO J. 19, 979–988.
inhibitor molecules in the unbiased |Fo|-|Fc|, φcalc maps (Figures 1A– Biondi, R.M., Komander, D., Thomas, C.C., Lizcano, J.M., Deak, M.,
1E). After initial rounds of model building, the inhibitor molecules Alessi, D.R., and van Aalten, D.M.F. (2002). High resolution crystal
were included in refinement, using topology and parameter files structure of the human PDK1 catalytic domain defines the regulatory
generated by PRODRG (van Aalten et al., 1996). Furthermore, elec- phosphopeptide docking site. EMBO J. 21, 4219–4228.
tron density for glycerol molecules, sulfate ions, and water mole-
Brazil, D.P., and Hemmings, B.A. (2001). Ten years of protein kinasecules could be observed, and these were included in the final mod-
B signalling: a hard Akt to follow. Trends Biochem. Sci. 26, 657–664.els, resulting in the final refinement statistics as shown in Table 2.
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P.,
Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M.,Mutational Analysis, Determination of Inhibition,
Pannu, N.S., et al. (1998). Crystallography & NMR system: a newand Specificity
software suite for macromolecular structure determination. ActaThe mutants PDK1[Val143Thr], PDK1[Leu159Met], PDK1[Ala162-
Crystallogr. D Biol. Crystallogr. 54, 905–921.Val], PDK1[Glu166Asp], PDK1[Thr222Ala], and the double mutant
PDK1[Val143Thr, Thr222Ala] were generated using site-directed Davis, P.D., Elliott, L.H., Harris, W., Hill, C.H., Hurst, S.A., Keech, E.,
mutagenesis with the QuikChange mutagenesis kit (Stratagene) in Kumar, M.K., Lawton, G., Nixon, J.S., and Wilkinson, S.E. (1992a).
the pEBG2T vector. PDK1 and the indicated mutants were ex- Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides
pressed as glutathione-S-transferase (GST) fusion proteins in 293 with improved potency and selectivity. J. Med. Chem. 35, 994–1001.
cells and purified as described previously (Biondi et al., 2002). Wild- Davis, P.D., Hill, C.H., Lawton, G., Nixon, J.S., Wilkinson, S.E., Hurst,
type PDK1 (Alessi et al., 1997) was assayed for 10 min at 30
C in a S.A., Keech, E., and Turner, S.E. (1992b). Inhibitors of protein kinase
50 l assay mixture in 50 mM Tris (pH 7.5), 0.1 mM EGTA, 0.1% C. 1. 2,3-Bisarylmaleimides. J. Med. Chem. 35, 177–184.
2-mercaptoethanol, containing 100 M substrate peptide (PDK1tide,
Davies, S.P., Reddy, H., Caivano, M., and Cohen, P. (2000). Specific-KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC), 10 mM mag-
ity and mechanism of action of some commonly used protein kinasenesium acetate, 100 M [-32P]ATP (200 cpm/pmol) as described
inhibitors. Biochem. J. 351, 95–105.previously (Biondi et al., 2000). Other protein kinases employed in
de Groot, B.L., Hayward, S., van Aalten, D.M., Amadei, A., and Ber-Table 1 were assayed as described previously (Bain et al., 2003;
endsen, H.J. (1998). Domain motions in bacteriophage T4 lysozyme:Davies et al., 2000).
a comparison between molecular dynamics and crystallographic
data. Proteins 31, 116–127.Chemistry of the BIMs
LY333531 was synthesized according to published procedures (Faul Eyers, P.A., Craxton, M., Morrice, N., Cohen, P., and Goedert, M.
et al., 1998; Jirousek et al., 1995, 1996). BIM-1, BIM-2, BIM-3, and (1998). Conversion of SB 203580-insensitive MAP kinase family
BIM-8 were synthesized according to the procedures published in members to drug-sensitive forms by a single amino-acid substitu-
Davis et al. (1992a) and Xie and Lown (1994). tion. Chem. Biol. 5, 321–328.
All figures were created with PyMol (www.pymol.org). Eyers, P.A., van den IJssel, P., Quinlan, R.A., Goedert, M., and Co-
hen, P. (1999). Use of a drug-resistant mutant of stress-activated
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